Showing 1221-1230 of 21420 results for "".
- Telehealth and Online CBT for High-Impact Chronic Painhttps://reachmd.com/news/telehealth-and-online-cbt-for-high-impact-chronic-pain/2487368/Key Takeaways Both remote 8-session CBT-based programs were associated with higher 3-month clinically important pain response rates than usual care. The health coach-led program showed better primary endpoint performance than the self-completed online
- Technology-Based Dry Eye Interventions Rank Differently by Outcomehttps://reachmd.com/news/technology-based-dry-eye-interventions-rank-differently-by-outcome/2487377/Key Takeaways Different technologies led different short-term endpoints, with TearCare plus meibomian gland expression topping gland secretion and IPL alone ranking highest for symptom relief. IPL-based approaches were associated with better tear break
- SCRATCH-AD: Rapid Itch Reduction, Biomarker Improvements with Ruxolitinibhttps://reachmd.com/news/scratch-ad-rapid-itch-reduction-biomarker-improvements-with-ruxolitinib/2487381/Patients with atopic dermatitis (AD) treated with ruxolitinib 1.5% cream experienced rapid and sustained reductions in itch alongside improvements in disease-associated biomarkers, according to findings from the SCRATCH-AD study. The open-label SCRATCH-AD trial (NCT04839380) evaluated the
- Linerixibat Improved Pruritus in Phase 3 PBC Trialhttps://reachmd.com/news/linerixibat-improved-pruritus-in-phase-3-pbc-trial/2487359/Key Takeaways Linerixibat was associated with greater pruritus improvement than placebo over 24 weeks. Gastrointestinal adverse events, especially diarrhea, were reported more often with linerixibat than with placebo. The randomized phase 3 co
- Avapritinib Shows Dermatologic Benefits in Indolent Systemic Mastocytosishttps://reachmd.com/news/avapritinib-shows-dermatologic-benefits-in-indolent-systemic-mastocytosis/2487380/Treatment with avapritinib led to substantial improvements in cutaneous disease manifestations among patients with indolent systemic mastocytosis (ISM), according to results from the phase 2 PIONEER study. Investigators for
- EHR Cognitive Load and Statin Initiation In Primary Carehttps://reachmd.com/news/ehr-cognitive-load-statin-initiation/2487346/Key Takeaways Longer encounter duration was associated with higher statin initiation, while longer time per EHR event was associated with lower initiation. Loop count followed a U-shaped pattern and distinct event count followed an inverse U-shaped pat
- Dual-Site aiTBS Reduces Suicidal Ideation in Adolescentshttps://reachmd.com/news/aitbs-suicidal-ideation-adolescents/2487338/Key Takeaways Dual-site aiTBS was associated with a greater day 4 reduction in suicidal ideation than single-site left DLPFC aiTBS. 59 adolescents were randomized to dual-site left DLPFC plus cerebellar aiTBS or active left DLPFC with sham cerebellar s
- Immigration Status Linked to Delayed Flash Glucose Monitoring Accesshttps://reachmd.com/news/immigration-flash-glucose-monitoring/2487327/Key Takeaways Matched immigrants had slower uptake of publicly funded flash glucose monitoring than matched long-term residents. Recent immigrants had the longest delay and lowest hazard, while long-term immigrants also showed a smaller persistent lag.
- Invizix Named Finalist in ADA 2026 Innovation Challengehttps://reachmd.com/news/invizix-named-finalist-in-ada-2026-innovation-challenge/2487317/Key Takeaways Invizix said it was named an ADA Innovation Challenge finalist and invited to present at Scientific Sessions. The company describes its platform as a sleep-time bioelectronic therapy intended to work in the background of daily life, inclu
- Brief DC/TMD Sensitivity For HaTMD Improved In Multicentre Studyhttps://reachmd.com/news/brief-dctmd-sensitivity-for-hatmd-improved-in-multicentre-study/2487313/Key Takeaways Reintroducing selected original examination items was associated with a marked improvement in sensitivity for headache attributed to TMD. Inter-examiner agreement for headache attributed to TMD diagnosis was almost perfect, with Cohen's k